Carlos Martin named Neurvati CCO

Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, has announced the appointment of Carlos Martin as chief commercial officer (CCO).

Mr Martin brings more than 20 years of leadership experience across global biopharmaceutical markets. Neurvati has cited his proven record of building commercial organizations, launching transformative therapies and strengthening pipeline valuation in highly innovative areas such as gene therapy, radiopharma, oncology, cardiology and rare diseases.

Most recently, Mr Martin was chief commercial officer at Rocket Pharma (Nasdaq: RCKT), where he oversaw the company’s transition from a clinical-stage biotech to a commercial-ready organization in gene therapies. There, he developed the company’s US, European and Japanese commercialization strategies and go-to-market models including infrastructure, and secured pre-launch payer agreements—all designed to accelerate market entry while bolstering investor confidence and company value.